Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ROS1-Alterations and Molecular Testing in Advanced NSCLC
16:28
16:28
Play later
Play later
Lists
Like
Liked
16:28
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
49:32
49:32
Play later
Play later
Lists
Like
Liked
49:32
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
34:45
34:45
Play later
Play later
Lists
Like
Liked
34:45
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Clinical Practice and NCCN Guidelines for CLL/SLL
31:33
31:33
Play later
Play later
Lists
Like
Liked
31:33
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
28:35
28:35
Play later
Play later
Lists
Like
Liked
28:35
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
24:23
24:23
Play later
Play later
Lists
Like
Liked
24:23
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for AML
25:21
25:21
Play later
Play later
Lists
Like
Liked
25:21
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
19:19
19:19
Play later
Play later
Lists
Like
Liked
19:19
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25:55
25:55
Play later
Play later
Lists
Like
Liked
25:55
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47:23
47:23
Play later
Play later
Lists
Like
Liked
47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
48:15
48:15
Play later
Play later
Lists
Like
Liked
48:15
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
36:29
36:29
Play later
Play later
Lists
Like
Liked
36:29
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Considerations for Adverse Event Management With HER3-Directed Agents
12:33
12:33
Play later
Play later
Lists
Like
Liked
12:33
The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
15:24
15:24
Play later
Play later
Lists
Like
Liked
15:24
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted anti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
8:54
8:54
Play later
Play later
Lists
Like
Liked
8:54
This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD A…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
30:29
30:29
Play later
Play later
Lists
Like
Liked
30:29
In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or plac…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
19:33
19:33
Play later
Play later
Lists
Like
Liked
19:33
In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: Navitoclax (BCL-XL/BCL-2 inhibitor) Pelabresib (BET inhibitor) Imetelstat (telomerase inhibitor) Luspatercept (erythroid maturation agent) Additional strategies Presenter: Jacqueline S. …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A Year in Review and a Look to the Future: BTKi in CLL and MCL
27:33
27:33
Play later
Play later
Lists
Like
Liked
27:33
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendam…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
33:18
33:18
Play later
Play later
Lists
Like
Liked
33:18
In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclit…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer
38:51
38:51
Play later
Play later
Lists
Like
Liked
38:51
In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Improving Care for Black Patients With Endometrial Cancer
26:58
26:58
Play later
Play later
Lists
Like
Liked
26:58
In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include: Data on racial disparities in EC survival Importance of listening to Black patients to better…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
24:54
24:54
Play later
Play later
Lists
Like
Liked
24:54
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including: Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/R…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023
20:58
20:58
Play later
Play later
Lists
Like
Liked
20:58
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for rela…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
14:39
14:39
Play later
Play later
Lists
Like
Liked
14:39
In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL BRUIN: updated results of pirtobrutinib in covalen…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023
27:03
27:03
Play later
Play later
Lists
Like
Liked
27:03
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of: CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL SEQUOIA: extended f…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
46:02
46:02
Play later
Play later
Lists
Like
Liked
46:02
In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including: ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab mainte…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers
31:38
31:38
Play later
Play later
Lists
Like
Liked
31:38
In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including: NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pemb…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma
32:21
32:21
Play later
Play later
Lists
Like
Liked
32:21
In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: Considerations with administration, including a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts
15:58
15:58
Play later
Play later
Lists
Like
Liked
15:58
In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including: Overall approach to treatment Use of JAK inhibitors for treating myelofibrosis Treating patients with low platelets Defining JAK inhibitor failure Unmet needs in treatment an…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
BRCA Testing and Adjuvant Therapy in Early Breast Cancer: Experiences and Challenges
25:05
25:05
Play later
Play later
Lists
Like
Liked
25:05
In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: Data supporting the use of adjuvant PARP in…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
15:48
15:48
Play later
Play later
Lists
Like
Liked
15:48
In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including: Expression patterns and function of the claudin family of proteins in normal gastric tissu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts
21:28
21:28
Play later
Play later
Lists
Like
Liked
21:28
In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include: When to use cytoreduction therapies and which therapies to use in low-risk patients Type 1 and type 2 CALR mutations and addressing patient concerns w…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia
26:12
26:12
Play later
Play later
Lists
Like
Liked
26:12
In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Answer Questions on the Management of Patients With T-Cell Lymphomas
16:27
16:27
Play later
Play later
Lists
Like
Liked
16:27
In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including: Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomas Strategies with JAK inhibition and epigenetic agents Allog…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes
21:59
21:59
Play later
Play later
Lists
Like
Liked
21:59
In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including: Practical use of the Molecular International Prognostic Scoring System Mutational targets and other treatments …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Individualizing Care for Patients With Triple-Negative Breast Cancer
36:17
36:17
Play later
Play later
Lists
Like
Liked
36:17
In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including: Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implicat…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Contemporary Approaches to Treating Polycythemia Vera: A Conversation Between Experts
15:51
15:51
Play later
Play later
Lists
Like
Liked
15:51
In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include: Patient presentation and goals of frontline therapy Considerations for second-line therapy in the setting of treatment intolerance Experts’ thoughts on t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
HCC Surveillance: Challenges and Opportunities
31:24
31:24
Play later
Play later
Lists
Like
Liked
31:24
In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance. Presenters: David E. Kaplan, MD, MSc Associate Professor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
9:23
9:23
Play later
Play later
Lists
Like
Liked
9:23
In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience. Presenter: Zoe Lanham Patient Link to full program: https://bit.ly/3Fukjzk…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Transgender Cancer Experience: A Conversation Between an Oncologist and a Transmasculine Individual on Navigating the Healthcare System
46:35
46:35
Play later
Play later
Lists
Like
Liked
46:35
In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include: 4 aspects of transgender care: emotional, social,…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers
27:21
27:21
Play later
Play later
Lists
Like
Liked
27:21
In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including: • Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer • Geneva HRD test: valida…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
10:33
10:33
Play later
Play later
Lists
Like
Liked
10:33
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include: Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registr…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting
21:46
21:46
Play later
Play later
Lists
Like
Liked
21:46
In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of: GLOW: phase III randomized t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
15:21
15:21
Play later
Play later
Lists
Like
Liked
15:21
In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including: Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ova…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape
1:18:59
1:18:59
Play later
Play later
Lists
Like
Liked
1:18:59
In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include: How to sequence currently available therapies after relapse Cha…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
19:39
19:39
Play later
Play later
Lists
Like
Liked
19:39
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including: Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo Phase III ENGOT-ov2…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
29:48
29:48
Play later
Play later
Lists
Like
Liked
29:48
In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on: • Identifying patients who may benefit the most from adjuvant osimertinib • Testing for EGFR mutations in early-stage NSCLC …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022
28:34
28:34
Play later
Play later
Lists
Like
Liked
28:34
In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management
26:12
26:12
Play later
Play later
Lists
Like
Liked
26:12
In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include: Factors to consider before selecting frontline immunotherapy Role of TKIs in the frontline Impact of Child-Pu…
…
continue reading